Prescription Drug Information: Prilosec

PRILOSEC- omeprazole magnesium granule, delayed release
Covis Pharma

1 INDICATIONS AND USAGE

1.1 Treatment of Active Duodenal Ulcer

PRILOSEC is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Triple Therapy

PRILOSEC in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.

Dual Therapy

PRILOSEC in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.

Among patients who fail therapy, PRILOSEC with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section].

1.3 Treatment of Active Benign Gastric Ulcer

PRILOSEC is indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.

1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)

PRILOSEC is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older.

1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD

Pediatric Patients 1 Year of Age to Adults

PRILOSEC is indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older.

The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered.

Pediatric Patients 1 Month to Less than 1 Year of Age

PRILOSEC is indicated for the short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age.

1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD

PRILOSEC is indicated for the maintenance healing of EE due to acid-mediated GERD in patients 1 year of age and older.

Controlled studies do not extend beyond 12 months.

1.7 Pathological Hypersecretory Conditions

PRILOSEC is indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Adult Dosage Regimen by Indication

Table 1 shows the recommended dosage of PRILOSEC in adult patients by indication.

Table 1: Recommended Dosage Regimen of PRILOSEC in Adults by Indication
Indication Dosage of PRILOSEC Treatment Duration
*
Most patients heal within 4 weeks; some patients may require an additional 4 weeks of therapy to achieve healing
The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered.
Dosage reduction to 10 mg once daily is recommended for patients with hepatic impairment (Child-Pugh Class A, B or C) and Asian patients when used for the maintenance of healing of EE [see Use in Specific Populations (8.6, 8.7) and Clinical Pharmacology (12.3, 12.5)].

Treatment of Active Duodenal Ulcer

20 mg once daily

4 weeks *

Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Triple Therapy

PRILOSEC 20 mg

Amoxicillin 1000 mg

Clarithromycin 500 mg

Take all three drugs twice daily

10 days

In patients with an ulcer present at the time of initiation of therapy, continue PRILOSEC 20 mg once daily for an additional 18 days for ulcer healing and symptom relief.

Dual Therapy

PRILOSEC 40 mg once daily

Clarithromycin 500 mg three times daily

14 days

In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of PRILOSEC 20 mg once daily is recommended for ulcer healing and symptom relief.

Active Benign Gastric Ulcer

40 mg once daily

4 to 8 weeks

Treatment of Symptomatic GERD

20 mg once daily

Up to 4 weeks

Treatment of EE due to Acid-Mediated GERD

20 mg once daily

4 to 8 weeks

Maintenance of Healing of EE due to Acid-Mediated GERD

20 mg once daily

Controlled studies do not extend beyond 12 months.

Pathological Hypersecretory Conditions

Starting dose is 60 mg once daily; adjust to patient needs

Daily dosages of greater than 80 mg should be administered in divided doses.

Dosages up to 120 mg three times daily have been administered.

As long as clinically indicated.

Some patients with Zollinger-Ellison syndrome have been treated continuously for more than 5 years.

2.2 Recommended Pediatric Dosage Regimen by Indication

Table 2 shows the recommended dosage of PRILOSEC in pediatric patients by indication.

Table 2: Recommended Dosage Regimen of PRILOSEC in Pediatric Patients by Indication
*
The efficacy of PRILOSEC used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of PRILOSEC may be considered.

Indication

PRILOSEC Dosage Regimen and Duration

Patient Age

Weight-Based Dose (mg)

Regimen and Duration

Treatment of Symptomatic GERD

1 to 16 years

5 to less than 10 kg: 5 mg

Once daily for up to 4 weeks

10 to less than 20 kg: 10 mg

20 kg and greater: 20 mg

Treatment of EE due to Acid-Mediated GERD

1 to 16 years

5 to less than 10 kg: 5 mg

Once daily for 4 to 8 weeks *

10 to less than 20 kg: 10 mg

20 kg and greater: 20 mg

1 month to less than 1 year

3 to less than 5 kg: 2.5 mg

Once daily up to 6 weeks

5 to less than 10 kg: 5 mg

10 kg and greater: 10 mg

Maintenance of Healing of EE due to Acid-Mediated GERD

1 to 16 years

5 to less than 10 kg: 5 mg

Once daily. Controlled studies do not extend beyond 12 months

10 to less than 20 kg: 10 mg

20 kg and greater: 20 mg

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Medication Sections

Medication Information by RSS

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2019. All Rights Reserved.